- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06784726
Odronextamab för recidiverande och refraktära storcelliga B-cellslymfom före CAR-T
Odronextamab för recidiverande/refraktära storcelliga B-cellslymfom före definitiva lymfomriktade terapier
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.
Studieöversikt
Status
Betingelser
- Återkommande diffust stort B-cellslymfom
- Refraktärt diffust stort B-cellslymfom
- Återkommande diffust stort B-cellslymfom, ej specificerat på annat sätt
- Refraktärt diffust stort B-cellslymfom, ej specificerat på annat sätt
- Återkommande höggradigt B-cellslymfom
- Refraktärt höggradigt B-cellslymfom
- Återkommande follikulärt lymfom grad 3b
- Refraktär grad 3b follikulärt lymfom
- Återkommande transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort B-cellslymfom
- Refraktärt transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort B-cellslymfom
- Återkommande primärt mediastinalt stort B-cellslymfom
- Refraktärt primärt mediastinalt stort B-cellslymfom
Intervention / Behandling
- Procedur: Bone Marrow Biopsy
- Övrig: Questionnaire Administration
- Procedur: Bone Marrow Aspiration
- Procedur: Lumbar Puncture
- Procedur: Positron Emission Tomography
- Procedur: Computed Tomography
- Procedur: Biopsy Procedure
- Procedur: Leukapheresis
- Biologisk: Odronextamab
- Procedur: Biospecimen Collection
- Biologisk: Chimeric Antigen Receptor T-Cell Therapy
Detaljerad beskrivning
OUTLINE:
Patients receive odronextamab intravenously (IV) on days 1, 2, 8, 9, 15 and 16 of cycle 1 (dose step-up), and on days 1, 8 and 15 of cycles 2-4 and then once every other week of remaining cycles. Cycles repeat every 21 days for the first 4 cycles, then every other week for up to a total of 12 months (including the first 2 cycles). After 2 cycles, patients undergo leukapheresis followed by lymphodepletion and CAR-T infusion per standard of care. If there is a significant delay of leukapheresis, patients may receive up to 12 additional weeks of treatment. Patients who achieve CR after cycle 2 may opt out of leukapheresis and CAR-T cell infusion and may continue to receive odronextamab in the absence of disease progression or unacceptable toxicity. Patients undergo positron emission tomography (PET)/computed tomography (CT), collection of blood and oral or rectal swab samples and tissue biopsy throughout the study. Additionally, patients may undergo lumbar puncture and bone marrow aspiration and/or biopsy on study.
After completion of study treatment, patients are followed till 90 days or the initiation of the next lymphoma directed therapy for toxicity check, and total duration of follow-up is up to 5 years.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Mengyang Di, MD, PhD
- Telefonnummer: 206-606-2519
- E-post: mydi@fredhutch.org
Studieorter
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98109
- Rekrytering
- Fred Hutch/University of Washington Cancer Consortium
-
Huvudutredare:
- Mengyang Di, MD, PhD
-
Kontakt:
- Mengyang Di, MD, PhD
- Telefonnummer: 206-606-2519
- E-post: mydi@fredhutch.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically confirmed large B cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, DLBCL arising from indolent lymphoma, follicular lymphoma (FL) grade 3B
- Measurable disease, defined as at least one measurable lesion ≥ 15 mm on PET, CT, or magnetic resonance imaging (MRI) within one month of screening, according to the International Working Group consensus response evaluation criteria in lymphoma
- Prior frontline therapy for large B cell lymphoma must have failed the patient, and criteria must be met for receiving commercial axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel) per Food and Drug Administration (FDA) label
- Age ≥ 18 years
- Capable of understanding and providing a written informed consent
- Prior treatment with an anti-CD20 antibody therapy
- Eastern Cooperative Oncology Group performance status of 0-1; we allow enrollment of patients with a performance status of 2 if it is attributed to lymphoma per discretion of the treating physician or principal investigator (PI)
- Creatinine clearance ≥ 45 mL/min calculated by Cockcroft-Gault equation
- Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x the ULN
- Adequate pulmonary function, defined as ≤ grade 1 dyspnea and oxygen saturation (SpO2) ≥ 92% on room air
- Adequate cardiac function, defined as left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
- Platelet count ≥ 75 x 10^9 /L
- Hemoglobin (Hg) level ≥ 9 g/dL
- Absolute neutrophil count (ANC) ≥ 1 x 10^9 /L
- Patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L
- Patients with bone marrow involvement or splenic sequestration: Hg ≥ 7.0 g/dL
- Patients with bone marrow involvement or splenic sequestration: ANC ≥ 0.5 x 10^9 /L
- Negative serum pregnancy test within 2 days of initiating odronextamab for women of childbearing potential (WOCBP), defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
- Fertile male and WOCBP patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the CAR T-cell infusion
- Patients must not provide egg or sperm donation until at least 6 months after the completion of the last dose of Odron
Exclusion Criteria:
- Detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of cerebrospinal fluid malignant cells or brain metastases. Patients with a history of secondary central nervous system (CNS) lymphoma may be eligible provided that there has been no evidence of CNS disease from lymphoma for at least 3 months at the time of screening
- History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement
- Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
- Standard radiotherapy within 2 weeks of first administration of study drug
- Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy, unless all the following are met: disease responded to prior bispecific therapy (CR or PR per Lugano criteria) and did not experience disease progression within 12 months of the last dose of prior bispecific therapy, and the tumor must still express CD20 (CD20 examination per standard of care [SOC])
- Allogeneic stem cell transplantation
- Any CAR-T cell therapy
- Patients may not be receiving other investigational agents
- Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
- Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
- Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
- History of allergic reactions attributed to compounds of similar chemical or biologic composition of study drug
- History of hypersensitivity to any compound in the tetracycline antibiotics group
- Concurrent active malignancy for which the patient is receiving systemic treatment, unless approved by PI
- Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection
- Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) and/or significant pulmonary disease (e.g., obstructive pulmonary disease and history of symptomatic bronchospasm)
- Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent. A short course of corticosteroid for lymphoma disease control during screening is allowed
- Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 400) or chronic infection with hepatitis B virus or hepatitis C virus. Patients with hepatitis B (hepatitis B surface antigen positive [HepBsAg+]) with controlled infection were permitted upon consultation with the physician managing the infection
- Known hypersensitivity to both allopurinol and rasburicase
- Pregnant or breast-feeding women
- Administration of live vaccination within 28 days of first administration of study drug
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (odronextamab)
Patients receive odronextamab IV based on the following schedules:
Please see the Detailed Description for additional information. |
Undergo bone marrow biopsy
Andra namn:
Ancillary studies Undergo bone marrow aspiration Undergo lumbar puncture
Andra namn:
Undergo PET/CT
Andra namn:
Undergo PET/CT
Andra namn:
Undergo tissue biopsy
Andra namn:
Undergo leukapheresis
Andra namn:
Given IV
Andra namn:
Undergo collection of blood and oral or rectal swab samples
Andra namn:
Undergo CAR-T cell therapy
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Failure to undergo leukapheresis
Tidsram: Up to 5 years
|
Will include failures due to disease progression or adverse events (AEs) due to odronextamab (Odron), or requirement of other lymphoma-directed therapy for bridging before leukapheresis due to lack of response. Will report the total number and percentage with 95% confidence interval (CI). |
Up to 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Receipt of chimeric antigen receptor T-cell therapy (CAR-T)
Tidsram: Up to 5 years
|
Will estimate the total number and percentage with 95% CI of patients who receive CAR-T cell infusion. Patients who achieve complete response (CR) after 2 cycles of Odron and opt out of leukapheresis will be excluded from the estimation of the percentage. Will also report the reasons why patients do not eventually receive CAR-T. |
Up to 5 years
|
|
Overall response rate (ORR) following bridging prior to CAR-T infusion
Tidsram: Up to 5 years
|
ORR includes CR, partial response, stable disease. Will report the total number and percentage with 95% CI of patients who achieve response on positron emission tomography/computed tomography (PET/CT) scans before CAR-T cell infusion. Patients who receive CAR-T cell infusion will be included in the estimation of this percentage. |
Up to 5 years
|
|
Progression free survival (PFS) following CAR-T infusion
Tidsram: Up to 2 years
|
Will estimate the median with interquartile range of the progression free duration. Will also report the percentage with 95% CI. |
Up to 2 years
|
|
CR rate
Tidsram: At 1 month after CAR-T
|
Will report the total number and percentage with 95% CI of patients who achieve CR on the PET/CT scans following CAR-T cell infusion. |
At 1 month after CAR-T
|
|
PFS in patients who achieve CR after 2 cycles of Odron, choose to opt out of CAR-T, and receive up to a total of 12 months of Odron
Tidsram: Up to 5 years
|
Will report the median duration of PFS with 95% CI in this group of patients. |
Up to 5 years
|
|
Incidence of AEs
Tidsram: Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first
|
All AEs will be graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome will be graded by the American Society for Transplantation and Cellular Therapy Consensus Grading systems. Will report the rate and grade of each AE, including unsuccessful CAR-T production. |
Up to 90 days after the last dose of Odron or the initiation of the next lymphoma directed therapy, whichever occurs first
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Lymfom, icke-Hodgkin
- Lymfom, B-cell
- Lymfom
- Hemiska och lymfsjukdomar
- Lymfom, stor B-cell, diffus
- Undersökningstekniker
- Terapeutik
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Punktering
- Kirurgiska ingrepp, operativ
- Cytologiska tekniker
- Cytodiagnos
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Biologisk behandling
- Cytapheres
- Blodkomponent
- Leukocytreduktionsförfaranden
- Cellseparation
- Diagnostiska tekniker, neurologiska
- Immunologiska tekniker
- Immunmodulering
- Adoptivöverföring
- Immunisering, passiv
- Immunisering
- Immunterapi
- Biopsi
- Provhantering
- Magnetresonansspektroskopi
- Leukaferes
- Ryggpunkter
- Immunterapi, adoptiv
Andra studie-ID-nummer
- RG1124641
- NCI-2024-10534 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- FHIRB0020747 (Annan identifierare: Fred Hutch/University of Washington Cancer Consortium)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .